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Abstract. 
 
Conventionally, nonsense mutations within a 
gene preclude synthesis of a full-length functional pro-
tein. Obviation of such a blockage is seen in the 
 
mdx
 
 
mouse, where despite a nonsense mutation in exon 23 
of the dystrophin gene, occasional so-called revertant 
muscle fibers are seen to contain near-normal levels of 
its protein product. Here, we show that reversion of 
dystrophin expression in 
 
mdx
 
 mice muscle involves un-
precedented massive loss of up to 30 exons. We de-
tected several alternatively processed transcripts that 
could account for some of the revertant dystrophins 
and could not detect genomic deletion from the region 
commonly skipped in revertant dystrophin. This, to-
gether with exon skipping in two noncontiguous re-
gions, favors aberrant splicing as the mechanism for the 
restoration of dystrophin, but is hard to reconcile with 
the clonal idiosyncrasy of revertant dystrophins. Rever-
tant dystrophins retain functional domains and mediate 
plasmalemmal assembly of the dystrophin-associated 
glycoprotein complex. Physiological function of rever-
tant fibers is demonstrated by the clonal growth of re-
vertant clusters with age, suggesting that revertant dys-
trophin could be used as a guide to the construction of 
dystrophin expression vectors for individual gene ther-
apy. The dystrophin gene in the 
 
mdx
 
 mouse provides a 
favored system for study of exon skipping associated 
with nonsense mutations.
Key words: reversion • dystrophin • nonsense muta-
tion • splicing • exon mapping
 
Introduction
 
Duchenne muscular dystrophy (DMD)
 
1
 
 is an X-linked
fatal muscular disease, characterized by the lack of dystro-
phin expression. The underlying genetic events are frame-
shift mutations in the dystrophin gene, which in man com-
prises 79 exons spanning 
 
.
 
2.4 million bp (Koenig et al.,
1987; Amalfitano et al., 1997). It encodes a 3685–amino
acid protein (427 kD) in skeletal muscles that can be di-
vided into NH
 
2
 
-terminal, rod, cysteine-rich, and COOH-
terminal domains. The NH
 
2
 
-terminal domain binds to cy-
toplasmic actin filaments and the cysteine-rich domain to
dystrophin-associated protein (DAP) complexes, includ-
ing dystroglycans, sarcoglycans, and syntrophins, through
which dystrophin connects itself to extracellular matrix
components. It has been suggested that dystrophin is in-
volved in force transmission from subsarcolemmal actin to
the extracellular matrix and protects fiber from contrac-
tion-related muscle damage (Winder et al., 1997). The
 
mdx
 
 mouse is a homologue of DMD and caused by a non-
sense point mutation in exon 23 of the gene (Bulfield et al.,
1984; Sicinski et al., 1989). Lack of dystrophin expression
in both DMD patients and 
 
mdx
 
 mouse results in chronic
degeneration and regeneration of skeletal muscles.
Surprisingly, individual dystrophin-positive muscle fi-
bers, called revertant fibers (RFs), have been observed in
otherwise dystrophin-negative backgrounds of both DMD
patients and 
 
mdx
 
 mouse. Revertant dystrophin, like nor-
mal dystrophin protein, shows a membrane localization,
suggesting that it may be functional. The incidence of RF
in muscles of DMD patients ranges from 0–70% (Burrow
et al., 1991; Klein et al., 1992; Fanin et al., 1995; Uchino
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et al., 1995), and comprises 
 
,
 
1% of fibers in the 
 
mdx
 
mouse (Hoffman et al., 1990; Nicholson et al., 1993). The
biological significance of the RF is not clear. Correlation
between the number of RFs in muscles and the clinical
prognosis of DMD patients has been inconclusive (Bur-
row et al., 1991; Nicholson et al., 1993; Fanin et al., 1995).
The mechanisms by which an individual dystrophic mus-
cle fiber acquires its ability to produce dystrophin from the
gene with out-of-frame mutations has yet to be deter-
mined. Exon skipping in association with nonsense muta-
tions has been reported in genes such as the factor VIII
gene in hemophilia A (Naylor et al., 1993), Fanconi ane-
mia group C genes (Gibson et al., 1993), fibrillin (FBN1)
gene in Marfan syndrome and in the ornithine 
 
d
 
-ami-
notransferase (OAT) gene in gyrate atrophy (Dietz et al.,
1993), transacylase (E2) gene of the human branched-
chain 
 
a
 
-keto acid dehydrogenase (BAKAD) complex in
maple syrup urine disease (MSUD) (Fisher et al., 1993),
and more recently in the 3-hydroxy-3-methylglutaryl-CoA
lyase gene (Pie et al., 1997). In the dystrophin gene, exon
skipping around point mutations has also been reported,
resulting in in-frame transcripts and shortened dystrophin
proteins (Shiga et al., 1997; Melis et al., 1998). These par-
ticular nonsense point mutations, which were not at the
consensus donor or acceptor splice sites, had presumably
disrupted the normal splicing by interfering with the splice
site recognition sequences.
We had previously identified several alternatively pro-
cessed dystrophin transcripts that skipped 5 to 11 exons,
including the mutated exon 23 in 
 
mdx
 
 mouse muscle (Wil-
ton et al., 1997a). However, it is difficult to determine
whether these mRNA transcripts detected by reverse tran-
scription (RT)-PCR from whole muscle tissue are relevant
to the production of dystrophin in RFs, which always form
a distinctive cluster (Hoffman et al., 1990). In the absence
of data relating them directly to RFs, these transcripts
could simply be the result of low-level random splicing
events.
To address these questions, we examined the dystrophin
in RFs of the 
 
mdx
 
 mouse at the protein, RNA, and DNA
levels. Serial muscle sections were examined with a panel
 
of exon-specific monoclonal and polyclonal antibodies
(Abs) by immunohistochemistry (Thanh et al., 1995). This
method enables us to analyze the patterns of exon com-
position of the revertant dystrophin within individual
RFs. We found that reversion of dystrophin expression in
 
mdx
 
 mice muscle utilizes mechanism(s) involving unprece-
dented massive exon skipping. The number of missing ex-
ons varied from a few to up to 30 in different RF clusters,
and several alternatively processed transcripts that are
consistent with the most common species of the shortened
proteins have also been detected. RFs appear to grow in a
clonal fashion, each cluster characterized by its individual
species of dystrophin. Revertant dystrophins are at least
partially functional, in that they protect the muscle fiber
from degeneration.
 
Materials and Methods
 
Tissues and Section Preparation
 
A total of 36 muscle samples from 26 male 
 
mdx
 
 mice aged from new born
to 20 mo were examined. Muscles of tibialis anterior and extensor digi-
torum longus (TE), quadriceps (QU), and posterior compartment (PC) of
hind legs were dissected and snap-frozen immediately after the animals
had been killed. Serial cross sections of 6 
 
m
 
m were cut onto 3-aminopro-
pyltriethxysilane (Sigma Chemical Co.) coated glass slides, numbered, and
stored at 
 
2
 
70
 
8
 
C. Sections of TE muscle from 
 
C57BL/10
 
 mouse were used
as controls.
 
Antibodies
 
A panel of 12 monoclonal and 2 polyclonal Abs against dystrophin were
used. These Abs recognize exons flanking the mutated exon 23 of the rod
region and in both NH
 
2
 
- and COOH-terminal domains of dystrophin. The
specificity, working dilution, and sources of the Abs are listed in Table I.
Titres of all antibodies were adjusted such that they produced approxi-
mately equal intensities of staining to each other on normal mouse muscle
and no staining on the bulk of fibers in 
 
mdx
 
 muscle, thus permitting broad
comparison of differences in intensity between individual revertant clus-
ters. mAb to 
 
b
 
-dystroglycan (43DAG/8D5; kind gift from Dr. L. Ander-
son, Muscular Dystrophy Unit, Newcastle, UK), polyclonal goat anti–
 
a
 
-sarcoglycan, anti–
 
b
 
-sarcoglycan, and anti–
 
a
 
-syntrophin (kind gifts from
K.P. Campbell, Department of Physiology and Biophysics, Howard
Hughes Medical Institute, University of Iowa College of Medicine, Iowa
City, IA) were also used.
 
Table I. Antibodies to Mouse Dystrophin
 
Names Clone Species Exon specificity Working dilution Sources and references
 
MANEX1A 4C7 M*/IgG1 1 1:3 Morris et al., 1995
 
a
 
60 Serum Sheep 10–18 1:500 Hoffman et al., 1987
MANDYS19 8F6 M/IgG1 20–21 1:4 Nguyen et al., 1990
MANDYS18 5H9 M/IgG2a 26 1:6 Nguyen et al., 1990
MANDYS16 1B12 M/IgG2b 27–28 1:4 Nguyen et al., 1990
NCL-DYS1 Dy4/6D3 M/IgG2a 26–29 1:3 Nicholson et al., 1989
MANDYS8 Ascites M/IgG2b 32 1:100 Sigma; Sedgwick et al., 1991
MANDYS110 3H10 M/IgG1 38–39 1:5 Nguyen and Morris, 1993
MANDYS101 7D12 M/IgG2b 40–41 1:4 Nguyen and Morris, 1993
MANEX45A 8F10 M/IgG1 45 1:4 Thanh et al., 1995
MANEX46B 7G1 M/IgG1 46 1:3 Thanh et al., 1995
MANEX50 6A9 M/IgG1 50 1:4 Thanh et al., 1995
p6 Serum Rabbit 57–60 1:500 Sherratt et al., 1992
MANDRA1 Ascites M/IgG1 77 1:100 Sigma; Ellis et al., 1990
 
*M, mouse.
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Nonspecific Background Blocking for the Use of mAb
 
A new blocking method was applied to prevent the binding of secondary
anti–mouse Ab to the endogenous mouse Igs or other mouse tissue com-
ponents when mAb was used (Lu and Partridge 1998). In brief, unlabeled
rabbit anti–mouse Igs (react with all mouse IgG subclasses, IgA, and IgM;
DAKO) and goat anti–mouse Igs (react with mouse IgG, IgA, and IgM;
DAKO) were digested with papain (5% of Igs, wt/wt; Sigma Chemical
Co.) to obtain monovalent Fab and Fc. The Fab-Fc was applied onto the
sections for 60 min before the primary Abs. Composite blocks of muscle
samples from 
 
C57BL/10
 
 and 
 
mdx
 
 mouse were used for optimizing the
condition with individual Abs.
 
Immunohistochemistry
 
Sections were air-dried, hydrated in PBS, and then subjected to either im-
munoperoxidase staining to produce permanent preparations, or immu-
nofluorescence method which permits better image recording and double
labeling. In brief, sections were incubated for 30 min with normal serum
(1:20) of the animals from which the second layer Abs was raised. For the
three-step immunoperoxidase method, sections were then incubated with
primary Ab for 1 h followed by biotinylated second layer Ab (rabbit anti–
mouse Igs, 1:400 dilution [DAKO]; or swine anti–rabbit Igs, 1:500
[DAKO]; or donkey anti–sheep/goat Igs, 1:500 dilution [Amersham Life
Science]) for 45 min. Endogenous peroxidase activity was blocked with
1% H
 
2
 
O
 
2 
 
in PBS for 10 min. Sections were then incubated with HRP-con-
jugated streptavidin (1:200; DAKO) for 45 min. Enzyme activity was de-
veloped with 3,3
 
9
 
-diaminobenzidine tetrahydrochloride (DAB, 1 mg/ml
PBS; Sigma Chemical Co.) and 0.1% H
 
2
 
O
 
2
 
 for 4 min. Finally, the sections
were counterstained with hematoxylin. For immunofluorescent staining,
sections after the secondary Ab were incubated with Texas red–conju-
gated streptavidin (1:200; DAKO) for 45 min and then counterstained
with 4
 
9
 
,6-diamidino-2-phenylindole (DAPI; Sigma Chemical Co.). All
Abs were diluted in 3% BSA in PBS unless otherwise stated, and inter-
vening washes carried out with PBS for 5 min twice. Negative controls
were carried out by replacing the primary Abs with 3% BSA in PBS or by
mAb NCL-DYS3 (Novocastro), which is specific for human dystrophin.
mAb NCL-spect2 (Novocastro) to 
 
b
 
-spectrin was used as a positive con-
trol for monitoring integrity of the sarcolemma membrane. Composite
sections of 
 
C57BL/10
 
 and 
 
mdx
 
 muscle with known RF were used for mon-
itoring positive and background staining.
For immunofluorescence double staining, sections were incubated with
both rabbit anti-dystrophin Ab p6, and one of the mAbs simultaneously
for 1 h, followed by Texas red–conjugated donkey anti–rabbit Igs (1:200;
Amersham Life Science) and FITC-conjugated goat anti–mouse Igs (1:50;
DAKO) for 45 min.
 
Detection of Alternatively Processed Dystrophin
Gene Transcripts
 
Total RNA was extracted from muscle of 
 
mdx
 
 mouse using an acid phenol
extraction as described by the manufacturer (RNAzol; Tel-Test Inc.). Ap-
proximately 50–100 ng of total RNA was used in a 12.5-
 
m
 
l single step
cDNA synthesis and primary DNA amplification reaction using Titan Ex-
pand (Boehringer Mannheim). The primary DNA amplification reaction
was carried out with the appropriate outer primers (Table II) for 40 cycles
of 90 (30 s), 55 (1 min), and 72
 
8
 
C (6 min). 1 
 
m
 
l was removed and reampli-
fied using the inner primers for 40 cycles of 90 (30 s), 55 (1 min), and 72
 
8
 
C
(6 min). The amplification products were fractionated on a 2% agarose
gel in Tris-acetate/EDTA buffer. RT-PCR products smaller than expected
were reamplified using bandstab (Wilton et al., 1997b) and purified using
Quiaquick PCR spin columns (Qiagen). Direct DNA sequencing was car-
ried out using the Big Dye chain terminator chemistry (PE Applied Bio-
Tech), where the products were fractionated and analyzed on an ABI 373
DNA sequencer.
 
Double Labeling of Immunohistochemistry and DNA In 
Situ Hybridization
 
Serial sections (10 mm) were cut from 18-mo-old male 
 
mdx
 
 mice and
stained first with anti-dystrophin Ab p6 followed by peroxidase-conju-
gated swine anti–rabbit Igs. Enzyme activity was developed with DAB
and 0.1% H
 
2
 
O
 
2
 
 for 4 min. Sections were then washed with PBS, digested
with RNase A (100 
 
m
 
g/ml for 1 h at 37
 
8
 
C; Sigma Chemical Co.), washed
with PBS, and dehydrated through graded ethanols.
A fragment of 7.2-kb mouse genomic DNA, from intron 21 to 5
 
9
 
 se-
quence of exon 25 of the dystrophin gene, was created and used as a probe
(sequence data available from EMBL/GenBank/DDBJ under accession
no. AF095738). Mouse genomic sequence of XIST gene and Y chromo-
some specific sequence Y1 were also used as positive control probes
(Nishioka, 1988). Probes were labeled with digoxigenin by nick translation
using Nick Translation System (Boehringer Mannheim). pBR322 DNA
was used as a negative control probe.
The hybridization protocol was essentially the same as described previ-
ously (Lu and Dover, 1993). The hybridization mixture consisted of deion-
ized formamide (50%), dextran sulphate (5%), 2
 
3
 
 SSC (1
 
3
 
 SSC
 
 5 
 
0.15 M
sodium chloride, 15 mM sodium citrate), sheared herring sperm DNA
(100 
 
m
 
g/ml), sodium dodecyl sulphate (0.1%), and the labeled probe (1
 
m
 
g/ml). 10–30 
 
m
 
l of hybridization mixture was applied on to immunohis-
tochemically stained sections, which were then covered and edge-sealed
with rubber solution. Probe and target DNA were denatured simulta-
neously for 8 min at 90
 
8
 
C, and hybridization was carried out at 42
 
8
 
C over-
night. Washes were carried out with 2
 
3
 
 SSC for 30 min at room tempera-
ture and 0.2
 
3
 
 SSC for 20 min twice at 40
 
8
 
C. Digoxigenin-labeled probes
were detected with FITC-conjugated sheep anti-digoxigenin Fab (1:20;
Boehringer Mannheim), followed by biotinylated goat anti-FITC Igs (1:
200; Vector Laboratory) and streptavidin/FITC (1:200; Amersham Life
Science). Sections were counterstained with 4,6-diamidino-2-phenylindole
(DAPI). Hybridization signals in 1,000 myonuclei in both RFs and adja-
cent non-RFs were counted.
 
Assessment
 
Muscle fibers were regarded as dystrophin-positive only when more than
half the membrane circumference was stained in cross sections. RFs adja-
cent to each other were characterized as a single cluster. Exon mapping of
revertant dystrophin was mainly carried out with three-step streptavidin
immunoperoxidase method on serial sections counterstained with hema-
toxylin, as they provide strong and permanent staining as well as morpho-
logical structure for subsequent time-consuming comparison. Double la-
belings were also carried out with one polyclonal Ab p6 and one of the
mAbs for confirmation. To avoid possible false negative results due to the
limited territory of dystrophin distribution along the axis of fiber, rever-
tant clusters were included in the exon mapping analysis only when posi-
tive staining was observed on both ends of a series of sections. For closer
comparison of RFs in mice of different age groups, 100 serial sections
(10-
 
m
 
m thick) of TE muscle from mice aged 0 (new born), 2 wk, 4 wk, 2 mo,
4 mo, and 18 mo (three mice per group) were stained with polyclonal Ab
p6 to exons 57–60. The number of revertant clusters, the number of RFs in
each clusters, and the length of RFs were counted. The total number of
RFs counted in all 100 sections was added and referred to as RF sections.
 
Results
 
RFs Are Observed in mdx Mouse Muscles of All Ages 
and Increase in Number, Size, and Length with Age
 
Dystrophin-positive fibers were seen in all muscles of new
born mice. Almost all RFs were isolated individual fibers;
even where a few RFs were concentrated in a small area,
they were not adjacent one to another (Fig. 1 A). These
RFs contained either centrally or peripherally localized
 
Table II.
 
Primer Sequence 5
 
9
 
 to 3
 
9
 
13F outer
 
GCT TCA AGA AGA TCT AGA ACA GGA GC
 
13F inner
 
CTC GCT CAC TCA CAT GGT AGT AGT G
 
35R outer
 
GGT GAC AGC TAT CCA GTT ACT GTT CAG
 
35R inner
 
GCC CAA CAC CAT TTT CAA AGA CTC TC
 
50R outer
 
CCA GTA GTG CTC AGT CCA GGG
 
50R inner
 
GGT TTA CAG CCT CCC ACT CAG
 
Primers used in the detection and characterization of alternatively processed dystrophin
gene transcripts. Other primers have been described in a previous publication (Wilton
et al., 1997a).
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nuclei. The dystrophin staining was generally weaker than
that seen in normal mouse muscle of same age, or RFs in
older mice.
At 2-wk-of-age, all fibers of 
 
mdx
 
 muscle contained pe-
ripheral nuclei, and showed no sign of degeneration. The
number of RFs increased significantly, largely reflecting
the increase of cluster size with up to five RFs per cluster.
By 4-wk-of-age, 
 
mdx
 
 mouse muscle was undergoing a
continuous process of degeneration and regeneration char-
acterized by the presence of necrotic fibers and centrally
localized nuclei. This was observed in all groups of older
mice. The overall number of RFs and the size of RF clus-
ters increased steadily over the lifetime of the mouse in
TE, quadriceps, and posterior compartment muscles. The
maximum number of RFs within one cluster was 11, 24, 34,
and 
 
.
 
100 in mice aged 4 wk, 2 mo, 4 mo, and 18 mo or
older, respectively (Fig. 1, B–D).
The growth of RF with age is best illustrated by the re-
sults of 100 serial sections (10-
 
m
 
m thick) of TE muscles as
summarized in Fig. 2. The total number of RF clusters
ranged from 41–48 (all single fibers) in new born mice, to
81 (maximum 40 RFs in one cluster) in 18-mo mice. Simi-
larly, the median length of RFs increased from 10 
 
m
 
m in
new born, to 510 
 
m
 
m in 18-mo mice. No RF cluster ex-
ceeded the span of sample length of 1 mm at 4 wk or
younger, but 
 
.
 
10% surpass this length at 4 mo and 30% at
18 mo. Most significantly, the average number of RFs in
each section was more than doubled between each age
group, from 0.73 RFs per section in new born mice to 141.1
per section in 18-mo mice. The increase in the number of
RF clusters with age was relatively small. This could be
due partly to the fact that the increased number of RFs
within an area made it difficult to distinguish each individ-
ual cluster.
RFs in mice aged 4 wk or older varied in size from hy-
pertrophic to small caliber myotubes seen in new born
mice, with mixed peripheral and centrally localized nuclei
(Fig. 1). RFs of small caliber often showed limited length
(
 
,
 
50 
 
m
 
m) despite the overall increase in the length of RF
and the size of revertant cluster. However, the intensity of
the staining was generally at similar levels within individ-
ual RFs except towards the ends of RF segments, which
showed weaker staining in serial sections.
 
Restoration of DAPs in RF
 
Protection of muscle fibers from degeneration depends on
restoration of DAPs by dystrophin. In 
 
mdx
 
 mice with a
functional dystrophin transgene, the level of sarcolemma-
bound DAPs was restored in skeletal muscles in associa-
tion with alleviation of muscular dystrophy (Dunckley et al.,
1993). Therefore, we examined the expression of DAPs in
RFs of 
 
mdx
 
 muscle. The majority of 
 
mdx
 
 muscle fibers
showed a greatly reduced level of 
 
b
 
-dystroglycans, 
 
a
 
- and
 
b
 
-sarcoglycans, and 
 
a
 
-syntrophin when compared with the
muscle fibers from normal C57 mouse. However, all four
proteins were clearly demonstrated in RFs at levels com-
parable to that observed in normal muscle of C57 mice
(Fig. 3). Variation in staining intensity with the four Abs
was seen within clusters of RFs, and appeared to be corre-
lated with the staining intensity of dystrophin. The restora-
tion of DAPs in RFs was seen in revertant clusters of all
sizes.
 
Dystrophin in RF Contains Functional Domains 
Despite Massive and Noncontiguous Exon Losses
 
Previous studies have shown that two domains of dystro-
Figure 1. Age-related expansion of RF in mdx mouse muscles.
(A) New born, (B) 4 wk, (C) 4 mo, and (D) 18 mo. The size of RF
clusters increases from isolated single fibers in the new born
mouse to a huge cluster containing .60 RFs in the 18-mo-old
mouse. Variation of RFs in size and of staining intensity within a
cluster is seen in mice aged 4 wk or older. Sections are stained for
dystrophin with polyclonal antibody p6.
Figure 2. An overall age-related increase of RFs in TE muscle of
mdx mouse. The number and length of RF clusters and maximum
number of RFs within one cluster increase steadily, resulting in a
huge increase in the number of RF sections within 1,000 mm of
TE muscles. NB, new born mice; W, weeks; M, months; and Maxi
No, maximum number. Vertical bars represent standard devia-
tion. The total number of RFs counted in all 100 sections was re-
ferred to as RF sections.
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phin are important for its function: the NH
 
2
 
-terminal do-
main and the cysteine-rich domain (Winder et al., 1997).
We examined revertant dystrophin with Abs to epitopes
flanking and within these two regions: Abs MANEX1A
 
(against exon 1) and 
 
a
 
60 (against exons 10–18) in the
NH
 
2
 
-terminal domain; and p6 (against exons 57–60) and
MANDRA1 (against exon 77) to the cysteine-rich
COOH-terminal domains. Dystrophin in nearly all RFs
was stained with these Abs and this was consistent in mice
of all ages. Only a few fibers (4%) lost the epitope in exon
77 recognized by MANDRA1. These fibers were stained
with MANEX1A, 
 
a
 
60, and P6 (Fig. 4). This result is con-
sistent with the membrane localization of revertant dystro-
phin in muscles of 
 
mdx
 
 mice of all ages.
Antibodies to the rod and hinge regions of dystrophin
produced surprisingly different results from those to the
NH
 
2
 
-terminal and cysteine-rich domains. Of a total of 279
RF clusters recognized by Abs to NH
 
2
 
-terminal and ex-
ons flanking cysteine-rich domains, 
 
,4% of RF clusters
were stained with the mAb MANDYS19 to exons 20 and
21, two exons upstream of the mutated exon 23. Simi-
larly, only 7.9% of the total RFs were stained with Ab
MANDYS18 to exon 26, three exons downstream of the
mutated exon 23. Increasing numbers of RFs were recog-
nized by Abs to exons towards the COOH-terminal rod
domain. RFs stained with p6 were nearly all recognized by
Ab MANEX50 to exon 50 (Fig. 5). Variations in exon loss
between different revertant clusters were observed within
each individual muscle as well as between different muscle
samples.
Although the majority of RFs expressed dystrophin
missing exons in one region adjacent to the point muta-
tion, four revertant clusters were found to have an exon
loss in a second region around the exons 32–45 (Fig. 5).
The frequency of exon loss involving two noncontiguous
regions is likely to be an underestimate, as the epitopes ex-
amined only covered a small number of exons.
Variation in intensity of dystrophin staining was also
observed. Weak positivity was often seen with Abs
MANDYS18, MANDYS16, and NCL-DYS1 to exons 26,
27 and 28, and 26–29, respectively, all of them recognizing
exons flanking the mutated exon 23 (Fig. 4). This signal
variation was not attributable to differences in the process
of immunohistochemistry, since other RFs with strong
Figure 3. Expression of dystrophin and dystrophin-associated
glycoprotein complex in RFs. A group of fibers are stained with
p6 for dystrophin. The same group of fibers are clearly stained
for b-dystroglycan, a- and b-sarcoglycan, and a-syntrophin and
the staining intensity is correlated to that of dystrophin. The re-
maining fibers are only weakly or not stained for the Abs. All fi-
bers are stained for spectrin (bottom left panel). Serial sections of
TE muscle from 18-mo-old mdx mouse.
Figure 4. Exon mapping of
RF. Staining of serial sections
with a panel of 12 Abs (name
above and exon specificity
below the pictures). Sections
are arranged in such an order
from left to right with Ab rec-
ognizing exons from NH2-ter-
minal to COOH-terminal.
The diagram below illustrates
the position of the epitope(s)
recognized by the Abs on the
dystrophin molecule. Serial
number of sections appears
at the bottom right corners.
Two isolated fiber clusters marked a and b with two and one fibers, respectively. Fibers a are recognized by Abs to NH 2-terminal exons
up to 18, but negative with Abs to exons 20–26. These fibers are positive with Ab to exons 27–28, but negative again with Abs to exons
from 26–29 to 38–39 followed by relatively weak staining with Ab to exons 40–41. Fiber b is recognized by Abs to NH 2-terminal ex-
ons up to 27–28, with relatively weak staining with Abs to exons 20–21. This fiber is not recognized with Ab against exons 26– 29 to
38–39. Another revertant fiber of small caliber stained with Abs to exons 26–29 and 50 appears at the bottom of the sections, which are
at the end of this serial sections. The primary Abs were detected with peroxidase method and the pictures are presented as negative im-
age to enhance contrast. Nuclei appear positive due to the haematoxylin counterstaining.
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staining were sometimes seen in the same microscopic
field.
Spliced mRNAs Predicted from Exon Mapping Are 
Readily Detected by RT-PCR
In an earlier study, alternatively processed dystrophin
gene transcripts were examined between exons 18 and 30
(Wilton et al., 1997a). Several species of transcripts with
exon skipping were detected in muscle of both mdx and
normal mouse, and some of them correlated with the exon
arrangement of the dystrophin protein in RFs. These tran-
scripts where exon 18 was spliced to exon 26 or 30 (in-
frame) could account for 15% of the dystrophin-positive
fibers observed by the exon mapping. However, these
transcripts did not reflect the most common isoforms of
revertant dystrophin predicted from the exon mapping re-
sults, many of which lack 20 or more exons. Therefore, new
exonic primers were selected to look for exon skipping
between exons 13 to 50 by Nested PCR. In addition to
the expected full-length product, shorter dystrophin tran-
scripts were also observed. One of the most commonly en-
countered alternative transcripts was an exon 18–35 splic-
ing, as confirmed by sequence analysis (Fig. 6 A). This
particular exonic rearrangement corresponds to 17% of
the RFs identified by the exon mapping. Another of the
shorter transcripts was found to have risen from exon 13,
being joined to exon 48 (Fig. 6 B). This transcript could
have directed synthesis of the most commonly encoun-
tered (25%) revertant dystrophin isoforms.
Detection of Genomic Sequence (Exons 22–25) in 
Nuclei of RF
More than 80% of RFs examined showed a loss of epi-
topes between exons 21 and 30. We sought to determine
whether deletion at the genomic level underlies the mas-
sive exon skipping at the mRNA and protein levels. How-
ever, examination of DNA extracted from muscle tissue
does not provide useful information, as the RFs account
for a very small proportion of muscle fibers. Attempts to
isolate possible revertant myoblasts from muscle culture
of mdx mouse has so far failed to establish any clones pro-
ducing revertant dystrophin (unpublished data). We there-
fore examined the serial sections from 18-mo-old mice
containing large RF clusters by combined immunohis-
tochemistry and DNA in situ hybridization. The revertant
dystrophins in these RFs were all negative with Abs
MANDYS19 (to exons 20 and 21) and MANDYS 18 (to
exon 26). Simultaneous detection of revertant dystrophin
protein and genomic sequence of intron 21 to exon 25
within individual RFs, would appear to rule out a genomic
deletion mechanism and imply a splicing-based exon skip-
ping. The results showed that the majority of nuclei in
muscles from both normal and mdx mice (84%) demon-
strated positive nuclear signal with the probe. A similar
proportion of nuclei within RFs (81%) was also found pos-
itive with the probe, indicating the presence of this region
at genomic level (Fig. 7). The difference in proportion of
hybridization-positive nuclei between RFs and non-RFs
was not statistically significant (P . 0.16), and there was
no difference in the intensity of signal between the two
populations. The lack of positive signals in a small propor-
tion of myonuclei in both RFs and non-RFs as well as nu-
clei of mesenchymal cells is mainly due to sectioning, since
the control XIST and Y1 probes labeled a similar propor-
tion of nuclei (data not shown).
Discussion
Revertant Dystrophin Is Functional
Mutations in the dystrophin gene can result in a spectrum
of phenotypes, ranging from almost asymptomatic to se-
vere DMD (Hoffman, 1993). Generally, the milder forms
Figure 5. Patterns of epitope
loss in RF. Total of 279 RF
clusters were examined with
14 Abs to dystrophin by
three-step immunoperoxidase
staining. Loss of 20 exons or
more was found in .65% of
RF clusters.
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of the muscular dystrophy are associated with in-frame de-
letions that permit the synthesis of shortened dystrophin
proteins with functional NH2- and COOH-terminal do-
mains. In some cases, massive genomic deletion, such as
from exons 17–48, 13–48, and 17–51, have been associated
with a mild form of the disease Becker muscular dystrophy
(BMD) (Love et al., 1991; Winnard et al., 1993; Mirabella
et al., 1998). Here, we show that in the mdx mouse, a vari-
ety of exon skipping events have created revertant dystro-
phins which bypass the original nonsense mutation. Exon
mapping indicated that the most common RFs arise from
the skipping of 10 or more exons, most frequently from
around exons 20 and 21 to around exon 32 (17%) or exon
46 (25%). We subsequently detected the predicted alter-
natively processed mRNA where exon 18 was joined to
exon 35, and 13 joined to exon 48. Although it is not possi-
ble to establish a causal link between any alternatively
processed mRNA and a particular RF, the exon mapping
result correlates well with some of the detected transcripts.
Despite considerable variation in the extent of exon
skipping between individual RFs, all revertant dystrophins
contained the intact NH2-terminal and cysteine-rich do-
mains, resulting in the reassembly of DAP complexes at
the sarcolemmal membrane. Interestingly, the most com-
monly encountered (25%) revertant dystrophin proteins
correspond to a massive human deletion that produced
only a mild Becker muscular dystrophy phenotype (Mira-
bella et al., 1998).
More direct evidence for function of the revertant dys-
trophins is the increase in size of RF clusters with increas-
ing age. Muscle repair in the mdx mouse is accomplished
by proliferation of myoblasts and fusion of these cells into
damaged segments of muscle fibers (Blaveri et al., 1999).
However, since dystrophin is not expressed in myogenic
cells, it can confer no advantage to them. This implies that
the increase in size of revertant clusters arises only by
Figure 6. Sequence profile of
the alternative dystrophin
transcript across exons 18–35
(A) and exons 13–48 (B) de-
tected by RT-PCR. The join-
ing sequences between exons
18 to 19, exons 34 to 35, exons
13 to 14, and exons 47 to 48
are shown above the graphs.
Both 39 of exons 13 and 18,
and 59 of exons 35 and 48 end
with complete codon (AAT,
AAG and GCT, GTC re-
spectively), and the resulting
transcripts are in-frame.
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preferential survival of muscle fiber segments which ex-
press revertant dystrophin.
Mechanisms Involved in the Restoration of Dystrophin 
Expression in RF
Since their discovery in dystrophic man and mouse, the na-
ture of revertant dystrophins in otherwise dystrophin-neg-
ative muscle has been an abiding mystery. Elucidation of
the underlying mechanisms responsible for the production
of revertant dystrophin has been severely hampered by
the combination of their low frequency, the multinuclear
nature of the muscle fiber, and sheer size of the dystrophin
gene (Burrow et al., 1991; Klein et al., 1992; Fanin et al.,
1995). Based on limited immunohistochemical analysis
and results from other systems, several theories have
been proposed, including somatic suppression, use of de-
velopmentally regulated alternative promoters, alternative
splicing, and somatic mutations (Hoffman et al., 1990;
Nicholson et al., 1993; Fanin et al., 1995; Winnard et al.,
1995; Darling et al., 1999). Our demonstration that almost
all revertant dystrophins in muscles of mdx mice lack par-
tial sequences around exon 23 argues strongly against so-
matic suppression as a cause of the revertant phenotype as
this mechanism would produce dystrophin of full length.
Similarly, all revertant dystrophins contained an intact
NH2-domain, showing that alternatively regulated known
promoters downstream of mutated exon 23 have not been
used. This leaves somatic mutations and alternative splic-
ing as the most plausible mechanisms for the generation of
in-frame transcripts from which shortened revertant dys-
trophins are translated.
Is Revertant Dystrophin a Result of Secondary 
Deletional Mutation?
The dystrophin gene appears to be prone to deletional
mutation, which accounts for up to 80% of BMD and 64%
of DMD cases. Deletions involving as many as 30 exons,
although extremely rare, have been reported (Chelly et al.,
1990; Love et al., 1991; Winnard et al., 1993). Clearly then,
deletional mutation must be considered as a potential
cause of the dystrophin expression in RF (Hoffman et al.,
1990; Fanin et al., 1995; Winnard et al., 1995; Thanh et al.,
1995). This would be consistent with the feature of clonal
growth and expansion of revertant clusters. The frequency
of RF and the rate of mutation in the human dystrophin
gene appear to be in approximate agreement too. Our best
estimate of the incidence of revertant foci comes from se-
rial sections spanning a 1-mm length of the belly portion of
TE muscles of new born mdx mice. Some 40–50 short
(10–20 mm) segments of single RF were identified in such
samples, each involving only 1 or 2 myofiber nuclei, and
presumably representing the differentiated product of a
single revertant myogenic cell lying nearby. The muscle
cross section comprises some 3,000–4,000 fibers, each con-
taining z100 nuclei/mm, giving an incidence of the rever-
sion event of 1:103 –1:104, which is slightly higher than the
frequency of new mutations in the DMD locus (Amalfi-
tano et al., 1997) during gametogenesis but not wildly dis-
parate.
However, it is difficult to square the pattern of RF with
a standard model of deletional mutation. Mutations are
generally proliferation-related random events, and there-
fore would most likely occur during the many divisions of
prenatal muscle development. In this instance, one might
expect to find big clusters of RFs in new born or young
mice as a result of prenatal clonal expansion. However,
this has not been observed in our survey of a large number
of mice younger than 6 wk.
Empirically, our failure to detect loss of corresponding
genomic sequences in the myonuclei of RFs by a combina-
tion of immunohistochemistry and in situ hybridization is
strong evidence against an explanation based on genomic
deletion. The detection rate with the probe of z80% in
the nuclei of both revertant and nonrevertant muscle fi-
bers is a common finding with probes to punctate markers
on sectioned material and implies that 100% of nuclei, or
very close to it, actually carry this region of the dystrophin
gene (Partridge et al., 1992). Thus, the majority, at least, of
nuclei in RF are not clonally derived from a myoblast with
large genomic deletion. One might conjecture that an un-
detectably small proportion of nuclei carrying deletions of
the gene could give rise to revertant dystrophin that be-
come dispersed over a large territory within the fibers.
However, the expansion of the myonuclear domain and
dispersion of dystrophin within a fiber are limited as dis-
cussed in a review by Allen et al. (1999) and shown in mdx
muscle fibers made mosaic by transplantation of normal
myoblast (Blaveri et al., 1999). We would expect to detect
a significant proportion of myonuclei with a genomic dele-
tion if this mechanism is responsible for producing the
near-normal amount of revertant dystrophin over large
territories in the majority of RFs. However, it should be
pointed out that mutations such as deletional mutations or
Figure 7. Combined immunohistochemistry and in situ hybrid-
ization for detection of dystrophin protein and genomic sequence
of intron 21 to exon 25. Dystrophin protein in RFs is stained with
immunoperoxidase method and the positive staining is shown as
false green color. Hybridization signals for the genomic region
of dystrophin sequences are shown as false red color. Nuclei
are counterstained with 4,6-diamidino-2-phenylindole (DAPI),
showing as blue. Sections are first stained with antibody p6 for
dystrophin on unfixed sections followed by in situ hybridization.
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point mutations affecting splicing may well be involved in
the production of revertant dystrophins, although such
events may be rare.
Is RNA Splicing Likely To Be the
Principal Mechanism?
Regulated alternative splicing of many genes is a feature
of muscle differentiation (Reed and Maniatis 1985; Streh-
ler et al., 1985; Breitbart and Nadal-Ginard 1987; Wiec-
zorek et al., 1988; Smith et al., 1989), and has also been
demonstrated in the expression of dystrophin, with exon 9
frequently being skipped from the mature mRNA in non-
muscle tissues (Reiss and Rininsland, 1994). At least three
distinct COOH-terminal sites, exons 68, 71–74, and 78,
show differential splicing (Feener et al., 1989; Bies et al.,
1992). To get direct evidence for the involvement of RNA
splicing in exon skipping of revertant dystrophin would re-
quire isolation of a cultured cell line that consistently ex-
presses revertant dystrophin. This has not proven possible
so far either in our laboratory or in another laboratory
where it has been attempted (Gussoni, E., personal com-
munication). Nonetheless, there is circumstantial support
for this mechanism. Firstly, aberrant splicing is the sim-
plest explanation of the finding of several transcripts with
variable numbers of skipped exons in muscles of both the
normal and the mdx mouse demonstrated here and previ-
ously (Wilton et al., 1997a). Secondly, although atypical
mutations involving two noncontiguous regions in the
same dystrophin gene have been reported (Zatz et al.,
1998), the probability of an in-frame transcript created by
two independent mutations should be ,0.01% when the
rate of single mutation is 1:103. It is therefore highly un-
likely that the high frequency (at least 10%) of two non-
contiguous exon skips could arise without involvement of
alteration in RNA splicing. Thirdly, exon 77 at dystrophin
COOH-terminal, which is often differentially spliced in
normal muscle (Feener et al., 1989), is missing in a propor-
tion of RFs, suggesting that alternative splicing of the gene
is operating in the RFs. In fact, this is the first demonstra-
tion of a dystrophin protein lacking exon 77, probably be-
cause the clonal nature of RF clusters makes it detectable
against a dystrophin-free background.
Lastly, the fact that RFs in new born mice are always
single and of limited length, rather than in clusters, sug-
gests that the revertant event is triggered at the stage of
myotube formation. Thus, the onset of the revertant phe-
notype corresponds well to that of muscle differentiation
at the time that imprinting of splicing machinery appears
to take place and regulated alternative splicing becomes
established. Such a splicing mechanism is consistent with
the presence of genomic regions that are skipped in the
protein of the revertant dystrophins.
Against the idea of splicing as the mechanism behind
production of revertant dystrophin is the apparent clonal
nature of expansion of RF clusters. To explain this in
terms of splicing, one would have to postulate a mecha-
nism by which each of at least 20 variants of splicing pat-
tern generated by random events could establish itself as a
predominant, efficient process and spread within a fiber
and to adjacent fibers. Although such mechanisms have
not been demonstrated, some observations suggest that
they may well exist in muscle. Thus, in Drosophila muscle
development, one particular myogenic cell can behave as a
founder to shape that character of the fiber by setting the
pattern of gene expression of the myonuclei within the fi-
ber (Rushton et al., 1995; Baylies et al., 1998). Secondly,
the skeletal muscles are known to be versatile for conver-
sion between different fiber types under conditions such as
stress and electric stimulation. This process is associated
with the use of alternative splicing in genes such as myo-
sins and TnT genes (Kelly and Rubinstein, 1994). By ex-
trapolation, one might conjecture that a particular set of
microenvironments might shape the pattern of gene ex-
pression by changing splicing pattern as well as switching
on/off different genes (Allen et al., 1999). The age-related
clonal expansion of RF in mdx mice suggests that one such
microenvironmental factor might be the process of local
muscle degeneration and regeneration. This is supported
by our unpublished observation that revertant dystrophins
could not be detected by immunohistochemistry in muscle
of normal mice, despite the presence of dystrophin mRNA
with a variety of exon skipping, though less abundant than
in mdx muscle (Wilton et al., 1997a). Also consistent with
this notion is RFs in utrophin transgenic mdx mice. The
expression of utrophin greatly diminishes muscle degener-
ation (Tinsley et al., 1998), and the size and number of re-
vertant clusters are much smaller in these mice than those
in mdx mice (unpublished observation). Thus, an aberrant
splicing pattern that produces a functional product might
be extended by selection as a predominant form to other
domains of the fiber and adjacent fibers in the process of
muscle degeneration and regeneration, but not in the nor-
mal muscles. This process would be enhanced if the func-
tional product is able to protect the fiber from degenera-
tion. The expansion of revertant dystrophin to a group of
fibers may also be accelerated by sharing a common cyto-
plasmic environment through fiber branching. The growth
in size of revertant cluster appears to be correlated well
with the extent of fiber branching, being most extensive in
the older mdx mice (Bockhold et al., 1998). The idea that
functional selection (imprinting) preserves the pattern of
random splicing certainly needs to be critically examined.
Clinical Significance
Understanding the exon composition of functional rever-
tant dystrophins is of clinical significance even though the
underlying mechanism is not clear. The lack of at least a
few exons in revertant dystrophins raises a question that
restoration of full-length dystrophin by gene therapy could
induce problems of immunogenicity. Therefore, it may be
important to characterize the commonly encountered re-
vertant isoforms so that a panel of functional dystrophin
transgenes can be designed for individual patients such as
to avoid immune rejection. We are also exploring the pos-
sibility of inducing specific exon skipping in the dystrophin
gene by using 2-0 methyl antisense oligonucleotides di-
rected at exon–intron junctions. Redirecting the splicing
process has allowed the skipping of exon 23 from the mdx
dystrophin mRNA (Wilton et al., 1999). However, this
shortened form of transcript only occurred at low levels,
with no demonstration of its protein and function. It may
therefore be necessary to target multiple exon–intron
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junctions to induce multiple exon splicing as observed in
revertant dystrophins.
A Model for Study of Functional Reversion of
Nonsense Mutations
Reports of evasion of nonsense mutations in other systems
are mainly based on the demonstration of RT-PCR–elic-
ited transcripts lacking the mutated exon and simply ex-
plained by RNA splicing (Dietz et al., 1993; Fisher et al.,
1993; Gibson et al., 1993; Naylor et al., 1993; Endo et al.,
1995; Lin et al., 1998). However, such PCR-based investi-
gations give no information on the spatial distribution of
the molecular events that generate these transcripts. In the
mdx and normal mouse, some readily demonstrable short-
ened in-frame transcripts (Wilton et al., 1997a) did not ap-
pear relevant to the protein products we found in RFs.
Conversely, transcripts responsible for expression of func-
tional dystrophin in RF, but produced by only a limited
number of cells, are likely to be concealed in a background
rich in various transcripts. In this light, no functional sig-
nificance can be attributed to in-frame transcripts gener-
ated by RT-PCR in the absence of protein products.
The nature of revertant dystrophin is unprecedented for
its sheer scale and complexity of exon skipping and its
clonal growth. This combination of properties presents the
conundrum of not being fully reconcilable with current
models of the mechanisms of gene transcription and trans-
lation and provides a unique model for elucidating the
complexity of exon skipping. This is attributable partly to
the large size of the dystrophin gene and the fact that a
high proportion of exons is bounded by complete codons,
a combination that gives a high probability of in-frame
transcripts from random exon skipping. The resulting
functional protein can localize to the membranes and pro-
tect the muscle fiber segments in which they occur, tending
to amplify their signal, highlighting them as rare events in
the null-background of dystrophic muscle. Few other
genes possess so extensive a range of properties that con-
spire to make their aberrant products conspicuous. The
dystrophin gene in the mdx mouse thus can be seen as an
especially favored system for detecting and studying such
events, but there is no special reason to think that the
mechanism underlying RFs is restricted to the dystrophin
gene.
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